Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House.
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
If you wonder whether Abbott Laboratories NYSE: ABT is a good buy in Q2 2025, the answer is yes. The company's management, portfolio, cash flow, capital return, and pipeline are why.
ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales beat expectations, with YoY growth rising to its highest point in 3 years, earnings merely met estimates, disappointing given the company's history of bottom-line beats averaging 9%. ABT's second-largest...
Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was too extreme. "I think this is a little bit of an overreaction.
Abbott Laboratories (ABT -8.52%) reported its second-quarter 2025 results on July 17, 2025, posting 7.5% organic sales growth (excluding COVID testing), 12% medical device growth, and adjusted EPS of $1.26, an 11% increase compared to the prior year and a 16% rise compared to the first quarter. Management reaffirmed its view of 2025 as a transition year marked by transient headwinds -- primaril...
Abbott Laboratories (NYSE:ABT ) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executive VP of Finance Robert B.
Abbott Laboratories (ABT -8.41%), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that narrowly topped analysts' consensus estimates. Q2 revenue climbed to $11.14 billion, surpassing the analyst estimate of $11.06 billion, and adjusted earnings per share came in at $1.26, beating the cons...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.